Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma
Jeffrey L. Wong, Jonathan E. Rosenberg
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 7, pp. 863-873
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Kaifeng Liu, Meijia Li, Yudong Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 49
Therapeutic prospects of nectin-4 in cancer: applications and value
Kaiyue Li, Yujing Zhou, Maolin Zang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 13
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
Puguang Yu, Chunming Zhu, Xiangyun You, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 10
Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with68Ga-N188
Jianhua Zhang, Xiaojiang Duan, Xueqi Chen, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. Supplement 1, pp. 12S-18S
Open Access | Times Cited: 8
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 6
Expression of Nectin-4 in Variant Histologies of Bladder Cancer and Its Prognostic Value—Need for Biomarker Testing in High-Risk Patients?
Severin Rodler, Lennert Eismann, Boris Schlenker, et al.
Cancers (2022) Vol. 14, Iss. 18, pp. 4411-4411
Open Access | Times Cited: 25
Nectin-4: a Novel Therapeutic Target for Skin Cancers
Hiroki Hashimoto, Yuka Tanaka, Maho Murata, et al.
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 4, pp. 578-593
Closed Access | Times Cited: 19
Assessment of targets of antibody drug conjugates in SCLC
Abhishek Ajay, Han Wang, Ali Reza Rezvani, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
X. Shi, Kai Tang, Quanbin Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
RP-HPLC can be used to determine an Enfortumab vedotin monoclonal antibody drug conjugate for treating urothelial cancer in an efficient rapid and quantitative manner
Chandra Sekhara Rao Gurugubelli, Suman Pallapati, Srinivasa Rao Pinapati
Analytical Chemistry Letters (2025), pp. 1-13
Closed Access
Progress in the study of antibody-drug conjugates for the treatment of cervical cancer
Cong-Cong Zhai, Yan Cui, Ling Guo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Current and Emerging Strategies to Treat Urothelial Carcinoma
Berkha Rani, James J. Ignatz-Hoover, Priyanka S. Rana, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4886-4886
Open Access | Times Cited: 9
E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies
Maoyu Wang, Zhensheng Zhang, Zhizhou Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis
Mirosława Püsküllüoğlu, Agnieszka Rudzińska, Renata Pacholczak‐Madej
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188991-188991
Open Access | Times Cited: 8
Expression of nectin-4 in prostate cancer
Melike Ordu
Northern Clinics of Istanbul (2023), pp. 583-588
Open Access | Times Cited: 6
Targeted therapies in bladder cancer: signaling pathways, applications, and challenges
Mei Peng, Xuetong Chu, Yan Peng, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 6
Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives
Raafat Alameddine, Patrick Mallea, Farhan Shahab, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 9, pp. 1167-1182
Closed Access | Times Cited: 5
Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies
Christopher A. Lucchesi, Demitria M. Vasilatis, Saisamkalpa Mantrala, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11395-11395
Open Access | Times Cited: 5
A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody–drug conjugates inspires robust tumor-specific immunological memory in solid tumors
Wenliang Sun, Yantong Li, Dezhi Sui, et al.
Biomaterials Science (2023) Vol. 11, Iss. 8, pp. 2787-2808
Closed Access | Times Cited: 4
Antibody-drug conjugates in solid tumors: a new frontier
Salvador Jaime-Casas, Regina Barragán-Carrillo, Abhishek Tripathi
Current Opinion in Oncology (2024) Vol. 36, Iss. 5, pp. 421-429
Closed Access | Times Cited: 1
Anti-Cancer Drug-Induced Lyell’s Syndrome: A Series of Two Patients
Julie Coussirou, Magali Ravoire, Alma Stancu, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6891-6897
Open Access | Times Cited: 1
Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma
Man Hagiyama, Takahiro Mimae, Akihiro Wada, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 4
Nectin-4: A promising prognostic marker and therapeutic target in cancer
Shilpa Kuttikrishnan, Kirti S. Prabhu, Ummu Habeeba, et al.
International review of cell and molecular biology (2024), pp. 223-255
Closed Access
Digital Papillary Adenocarcinoma Is HPV-42-Associated and BRAFV600E Negative: Perspectives for Diagnostic Practice
Tassilo Dege, Arno Rütten, Matthias Goebeler, et al.
Dermatopathology (2024) Vol. 11, Iss. 4, pp. 348-353
Open Access
Page 1 - Next Page

Scroll to top